伏立康唑序贯治疗慢性阻塞性肺疾病急性加重期合并肺曲霉菌病的临床分析  

Clinical analysis of Voriconazole in the treatment of invasive pulmonary aspergillosis in patients with acute exacerbation of chronic obstructive pulmonary disease

作　　者：张杰根[1] 蔡然[2] 戴富林[1] 

机构地区：[1]河北省涿州市医院呼吸内科,河北涿州072750 [2]河北省涿州市医院药剂科临床药学室,河北涿州072750

出　　处：《中国医药导报》2013年第8期74-76,共3页China Medical Herald

基　　金：河北省保定市科学技术研究与发展指导计划项目(项目编号:12ZF040)

摘　　要：目的观察慢性阻塞性肺疾病急性加重期合并肺曲霉菌感染的临床特点及伏立康唑的临床疗效,为临床治疗提供依据。方法结合文献及临床病例回顾分析36例河北省涿州市医院收治的慢性阻塞性肺疾病急性加重期合并肺曲霉菌感染患者的临床资料及伏立康唑治疗的效果。结果慢性阻塞性肺疾病急性加重期合并肺曲霉菌感染临床表现缺乏特异性,病情危重,但经伏立康唑早期序贯治疗后痊愈率可达25.0%(9/36),有效率为58.3%(21/36)。结论早期积极应用伏立康唑序贯治疗,可提高慢性阻塞性肺疾病急性加重期合并肺曲霉菌感染的临床疗效,降低病死率。Objective To provide evidence for clinical treatment of Voriconazole through observing clinical features of invasive pulmonary aspergillosis（IPA） in patients with acute exacerbation of chronic obstructive pulmonary disease（AECOPD） and clinical effect of Voriconazole.Methods Clinical data and Voriconazole efficacy of 36 AECOPD cases with IPA of Zhuozhou hospital in Hebei Province were retrospectively analyzed combined with the literature.Results AECOPD complicated with IPA lacked clinical specificity and the patient＇s condition always be serious.However,the clinical recovery and effective rate of Voriconazole were increased to 25.0%（9/36） and 58.3%（21/36） through an early sequential therapy of Voriconazole.Conclusion Early rational utilization of Voriconazole will improve the clinical efficacy of AECOPD complicated with IPA and reduce mortality.

关 键 词：伏立康唑 慢性阻塞性肺疾病 肺曲霉菌 

分 类 号：R563.1[医药卫生—呼吸系统]